Wells Fargo’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-98,896
| Closed | -$3.89M | – | 7800 |
|
|
2023
Q2 | $3.89M | Buy |
98,896
+15,202
| +18% | +$537K | ﹤0.01% | 2349 |
|
|
2023
Q1 | $2.04M | Buy |
83,694
+77,154
| +1,180% | +$1.69M | ﹤0.01% | 2840 |
|
|
2022
Q4 | $140K | Sell |
6,540
-7,118
| -52% | -$152K | ﹤0.01% | 4361 |
|
|
2022
Q3 | $245K | Sell |
13,658
-2,662
| -16% | -$34.9K | ﹤0.01% | 4123 |
|
|
2022
Q2 | $156K | Sell |
16,320
-51,510
| -76% | -$647K | ﹤0.01% | 4411 |
|
|
2022
Q1 | $1.14M | Sell |
67,830
-38,937
| -36% | -$575K | ﹤0.01% | 3768 |
|
|
2021
Q4 | $1.78M | Buy |
106,767
+76,030
| +247% | +$1.25M | ﹤0.01% | 3613 |
|
|
2021
Q3 | $500K | Buy |
30,737
+11,190
| +57% | +$122K | ﹤0.01% | 4663 |
|
|
2021
Q2 | $123K | Sell |
19,547
-22,345
| -53% | -$144K | ﹤0.01% | 5220 |
|
|
2021
Q1 | $259K | Sell |
41,892
-132,323
| -76% | -$803K | ﹤0.01% | 5040 |
|
|
2020
Q4 | $1.2M | Buy |
174,215
+57,100
| +49% | +$365K | ﹤0.01% | 3890 |
|
|
2020
Q3 | $662K | Buy |
117,115
+93,223
| +390% | +$445K | ﹤0.01% | 4151 |
|
|
2020
Q2 | $123K | Buy |
23,892
+23,253
| +3,639% | +$96.9K | ﹤0.01% | 5138 |
|
|
2020
Q1 | $2K | Sell |
639
-100
| -14% | -$584 | ﹤0.01% | 6028 |
|
|
2019
Q4 | $7K | Hold |
739
| – | – | ﹤0.01% | 5986 |
|
|
2019
Q3 | $0 | Sell |
739
-27,190
| -97% | -$31.6K | ﹤0.01% | 6838 |
|
|
2019
Q2 | $36K | Sell |
27,929
-22,945
| -45% | -$31.5K | ﹤0.01% | 5657 |
|
|
2019
Q1 | $72K | Buy |
50,874
+11,239
| +28% | +$15.7K | ﹤0.01% | 5235 |
|
|
2018
Q4 | $47K | Buy |
39,635
+3,618
| +10% | +$7.01K | ﹤0.01% | 5547 |
|
|
2018
Q3 | $84K | Sell |
36,017
-1,400
| -4% | -$3.49K | ﹤0.01% | 5424 |
|
|
2018
Q2 | $102K | Buy |
37,417
+2,075
| +6% | +$5.72K | ﹤0.01% | 5371 |
|
|
2018
Q1 | $96K | Buy |
35,342
+2,182
| +7% | +$6.33K | ﹤0.01% | 5324 |
|
|
2017
Q4 | $103K | Buy |
33,160
+21,411
| +182% | +$60.2K | ﹤0.01% | 5292 |
|
|
2017
Q3 | $33K | Buy |
11,749
+11,650
| +11,768% | +$31.5K | ﹤0.01% | 5587 |
|
|
2017
Q2 | $0 | Sell |
99
-72,157
| -100% | -$197K | ﹤0.01% | 6519 |
|
|
2017
Q1 | $264K | Sell |
72,256
-24,279
| -25% | -$103K | ﹤0.01% | 4638 |
|
|
2016
Q4 | $465K | Sell |
96,535
-242,855
| -72% | -$7.21M | ﹤0.01% | 4246 |
|
|
2016
Q3 | $15.7M | Sell |
339,390
-13,029
| -4% | -$735K | 0.01% | 1455 |
|
|
2016
Q2 | $18M | Buy |
352,419
+288,514
| +451% | +$14.3M | 0.01% | 1398 |
|
|
2016
Q1 | $2.7M | Sell |
63,905
-3,151
| -5% | -$161K | ﹤0.01% | 2706 |
|
|
2015
Q4 | $5.26M | Buy |
67,056
+26,721
| +66% | +$1.55M | ﹤0.01% | 2284 |
|
|
2015
Q3 | $1.64M | Buy |
40,335
+2,664
| +7% | +$141K | ﹤0.01% | 3143 |
|
|
2015
Q2 | $1.96M | Buy |
37,671
+2,524
| +7% | +$126K | ﹤0.01% | 3111 |
|
|
2015
Q1 | $1.64M | Buy |
35,147
+4,574
| +15% | +$237K | ﹤0.01% | 3185 |
|
|
2014
Q4 | $1.37M | Buy |
30,573
+4,258
| +16% | +$179K | ﹤0.01% | 3299 |
|
|
2014
Q3 | $1.02M | Sell |
26,315
-712
| -3% | -$27.9K | ﹤0.01% | 3449 |
|
|
2014
Q2 | $1.14M | Buy |
27,027
+712
| +3% | +$26.1K | ﹤0.01% | 3427 |
|
|
2014
Q1 | $938K | Buy |
26,315
+26,313
| +1,315,650% | +$888K | ﹤0.01% | 3542 |
|
|
2013
Q4 | $0 | Buy |
+2
| New | +$59 | ﹤0.01% | 5982 |
|
Wells Fargo's ISEE Position: Q3 2023 in Review
Wells Fargo sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 98,896 shares — an estimated $3.89M sold.
Wells Fargo first reported a position in ISEE in Q4 2013 and held it in 39 quarters. The position peaked at $18M in Q2 2016. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- Wells Fargo reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Wells Fargo sold 98,896 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $3.89M.
- Wells Fargo first reported a position in IVERIC bio, Inc. Common Stock in Q4 2013 and held it in 39 quarters.
- Wells Fargo's IVERIC bio, Inc. Common Stock position peaked at $18M in Q2 2016.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on Wells Fargo's 13F filing for Q3 2023, filed 13 Nov 2023.